CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
- Status
- COMPLETED
- Phase
- PHASE2
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE3
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
- Status
- COMPLETED
- Phase
- PHASE2
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
- Status
- UNKNOWN
- Phase
- PHASE3